跳至主要内容
临床试验/NCT03409783
NCT03409783撤回不适用

A Multicenter Randomized Controlled Trial Evaluating the Effectiveness of the Enso Device for Treatment of Chronic Low Back Pain in Relation to Study Entry Criteria

Thimble Bioelectronics, Inc.4 个研究点 分布在 1 个国家开始时间: 2018年2月14日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
撤回
发起方
试验地点
4
主要终点
Six Minute Walk Test

研究概览

简要总结

Enso is a portable device for the treatment of chronic and acute types of musculoskeletal pain. This study is being designed as a single blind, sham-controlled randomized clinical trial.

详细描述

Fifty subjects will be selected based on the inclusion criteria and then randomized to either the intervention group or the sham control group. Each subject will be randomly fitted with an Enso or a sham device and will be instructed to self-administer treatment daily for one hour or more per day for two weeks in both cohorts. Throughout the duration of the study, data will be recorded via a smartphone application regarding treatment usage and intensity, pain levels, the subject's impression of any changes in their functionality, and their opioid and non-opioid medication intake. Additional functional testing will be conducted at each study visit.

At the 2 week visit, the study blind will be broken, and subjects who were randomized to the sham group will be given the opportunity to cross over for an additional 2 week period using the active device.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

盲法说明

Devices are assigned per the randomization schedule, with the sham device identical to the active device in every way except that no neuromodulation is delivered. The neuromodulation that the active device delivers can be done in a way that causes no sensation, so subjects are not unmasked.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Walk no further than 250 meters during a pre-study administration of the Six Minute Walk Test
  • Confirm that either they are able on their own to place the device (i.e., the gel pad) in its proper location, or they have a caretaker or family member who can assist them if needed
  • Mechanical (myofascial), axial back pain (focused around the spine)
  • 6/10 or greater level of pain
  • Functionally debilitated by their pain (e.g., difficulty walking)
  • Minimal radicular symptoms with no effect on functionality, medication, quality of life
  • Expressed desire to stop taking pain medications
  • Expressed desire to improve disability
  • 80% or greater of disability is due to pain in the low back (as opposed to other body areas)
  • Experiencing chronic pain for at least 6 months
  • Interested in being active, improving their functionality
  • Comfortable with using technology in daily life
  • Subject able to understand and grant informed consent
  • Documented adherence with clinic follow up visits per medical records
  • Has an email account
  • Above 18 years old

排除标准

  • Patients that do not own or have access to a smartphone
  • Subject who, in the Investigator's opinion, does not demonstrate a strong desire to reduce opioid or other pain medication usage (e.g., opioid dependence)
  • Has spinal instability, joint instability, or grade 2 or greater spondylolisthesis with instability
  • Primary symptoms due to spinal stenosis
  • Source of back pain related to an acute nerve impingement
  • Diagnosis of cancer/malignant tumors in the last 5 years
  • Source of back pain is an infection
  • Prior spinal fusion surgery
  • Has a cardiac pacemaker, implanted defibrillator or other implanted electronic device
  • Has radicular pain symptoms that account for more than 20% of their pain and/or functional impairment
  • Has undergone surgery to solve pain related to the study indication in the past 6 months
  • Patients with history of opioid, alcohol or drug abuse in the last 5 years, per investigator discretion
  • Any psychiatric condition that may interfere with the study assessments or prevent the subject from complying with the requirements of the protocol, in the judgement of the investigator.
  • Inability to complete subjective data as required; e.g. on mobile application and questionnaires
  • Pregnant women (as determined by self-report)
  • Have severe epilepsy
  • Have severe form of cardiovascular disease
  • Any other disease, condition, or habit(s) that in the opinion of the Principal Investigator would interfere with study compliance or adversely affect study outcomes

研究组 & 干预措施

Active or ENSO Group

Active Comparator

Active ENSO device use for two weeks, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.

干预措施: ENSO Device (Device)

Sham Group

Sham Comparator

Sham device use for two weeks, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.

干预措施: Sham Device (Device)

结局指标

主要结局

Six Minute Walk Test

时间窗: Once a week for two weeks

Compare the change in patient's 6 Minute Walk Test (6MWT) between the Enso intervention group and the sham group using the validated 6MWT procedure.

次要结局

  • Functional back pain assessment(Once a week for two weeks)

研究者

发起方
Thimble Bioelectronics, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验